美国的Sanaria生物技术公司正在开发疟疾疫苗PfSPZ,其作用机制是通过诱发抗体反应以及产生更多攻击“外来入侵者”的(免疫系统)T-细胞来对付棘手的疟原虫。Sanaria的候选疫苗是灭活型完整寄生虫,而不只是疟原虫的片段,这样可以产生更广泛的免疫反应。到目前为止,这种作用途径看来是有效 The Sanaria biotech company in the United States is developing PfSPZ, a malaria vaccine that works to counter the thrips of Plasmodium falciparum by inducing antibody responses and generating more (immune system) T-cells that attack “alien invaders.” Sanaria’s vaccine candidate is an inactivated complete parasite, not just a fragment of the malaria parasite, which produces a broader immune response. So far, this route of action seems to be effective